Therapeutic advances in gastroenterology
Cure8 research brief
Why This Matters
EoE causes swallowing problems and can overlap with other immune-driven conditions. Knowing how common EoE is among people with IBD or type-2 inflammatory diseases may prompt clinicians to screen patients with unexplained dysphagia.
Who Should Pay Attention
Adults with IBD or type-2 inflammatory diseases (asthma, chronic rhinosinusitis with polyps, atopic conditions), gastroenterologists, and researchers interested in disease overlap and diagnosis.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
Researchers screened 687 patients with IBD or type-2 inflammatory conditions using a dysphagia questionnaire and offered endoscopy with esophageal biopsies to those with relevant symptoms. Six new EoE cases were diagnosed and seven were previously known, suggesting EoE may be under-recognized in these patient groups.
Endoscopy with biopsy was used to confirm EoE; not all patients with relevant dysphagia underwent study endoscopy because some had recent prior procedures. The study is cross-sectional and reports prevalence from two Austrian centers, so findings reflect the screened population rather than proving a causal link between IBD/type-2 conditions and EoE.
Keep In Mind
Study is cross-sectional from two centers; not all symptomatic patients had endoscopy during the study because some had recent prior procedures. Prevalence reflects the screened cohort and does not establish causation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationTherapeutic advances in gastroenterology
AuthorsMartin Bäuerle, Jurij Maurer, Jagoda Pokryszka +13 more
InstitutionDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 28, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: P.S. received consulting fees from AbbVie, Falk Pharma, Janssen-Cilag, Takeda, Alfasigma, Pfizer, Sanofi-Aventis, AstraZeneca. G.N. received lecture fees/consultant fees/advisory board member fees from AbbVie, Merck Sharp & Dohme, Takeda, Janssen-Cilag, Pfizer, Gilead, Galapagos/Alfasigma, Ferring, Vifor, AstroPharma, Falk, Bristol Myers Squibb, Arena Pharmaceuticals, and Amgen. S.W. received consulting fees from Novartis, Sanofi, ThermoFisher Scientific. A.F. received travel support from Takeda, Amgen, Johnson & Johnson, and AbbVie. C.B. has been a clinical trial investigator for Almirall, Pfizer, AbbVie, Eli Lilly and Company, Galderma, LEO Pharma, Novartis, and Sanofi Genzyme, and an advisory board member, consultant, and/or invited lecturer for Pfizer, AbbVie, ALK, Almirall, Eli Lilly and Company, Incyte, LEO Pharma, A. Menarini Pharma, Schuelke & Mayr GmbH, Galderma, Novartis, and Sanofi Genzyme. SS reports grants, payment for lectures, and participation on advisory boards from Sanofi, AstraZeneca, and GSK. M.T.: received grant support from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx, honoraria for consulting from AbbVie, Albireo, Agomab, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Janssen, Mirum; MSD, Novartis, Phenex, Pliant, ProQR Therapeutics, Regulus, Siemens and Shire, speaker fees from Albireo, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Gilead, Ipsen, Intercept, MSD and Madrigal, as well as travel support from AbbVie, Falk, Gilead, Janssen and Intercept, Ipsen and Janssen. He is also a co-inventor of patents on the medical use of 24-norursodeoxycholic acid filed by the Medical University of Graz. W.R. has served as a speaker, consultant, advisory board member, and/or received research funding from AbbVie, Amgen, AOP Orphan, Arena, Astellas, AstraZeneca, Bioclinica, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Celgene, Celltrion, Dr Falk, Ferring, Galapagos, Gatehouse, Genentech, Gilead, Grünenthal, ICON, InDex, Inova, Janssen, Landos, Lilly, Medahead, MedImmune, Microbiotica, Mitsubishi Tanabe, MSD, Novartis, OMass, Otsuka, Parexel, Peri Consulting, Pharmacosmos, Pfizer, Protagonist, Provention, Quell, Roche, Sandoz, Sanofi, Seres, SetPoint Medical, Shire, Sigmoid, Sublimity, Takeda, Teva, Therakos, Theravance, and Zealand.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
Fecal incontinence among patients with ulcerative colitis and relation with disease activity, and extent: A cross-sectional study.
Fecal incontinence is a distressing symptom that lowers quality of life and appears linked to active disease in UC. Knowing which patients are at higher risk can help clinicians focus assessment and symptom support.
Fatigue in inflammatory bowel disease beyond intestinal inflammation: A cross-sectional study.
Fatigue is common and disabling for people with IBD; this study shows that factors beyond intestinal inflammation—especially central sensitization and psychological symptoms—explain much of fatigue. That means treating...
Underevaluation of bowel urgency in clinical care: patient experiences and outcomes in ulcerative colitis: a retrospective cohort study
Bowel urgency is a common symptom that may predict higher risk of treatment escalation, hospitalization, or surgery in UC even when bleeding and stool frequency look controlled. Better assessment of urgency in clinic...